{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:37:31Z","timestamp":1789641451278,"version":"4.0.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.antiviral.2013.05.015","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T05:56:46Z","timestamp":1370584606000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics"],"prefix":"10.1016","volume":"99","author":[{"given":"Eric","family":"Lawitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Maliakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Al-Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen Kurt","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Panorchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy May","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Gress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Mobashery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.antiviral.2013.05.015_b0005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.05.015_b0010","unstructured":"Barnard, R.O., Feng, M., Ramos, G., Himmelberger, A., Miller, M.L., Graham, D., Ludmerer, S.W., Carroll, S.S., Olsen, D.B., Quirk, E.K., Hazuda, D.J., 2009. Analysis of antiviral resistance to MK-7009 in Protocol 004, a phase 1b monotherapy study. In: 4th International Workshop on Hepatitis C, Resistance and New Compounds, Boston, MA, USA (Abstract)."},{"issue":"4","key":"10.1016\/j.antiviral.2013.05.015_b0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in the United States","volume":"9","author":"Davis","year":"2003","journal-title":"Liver Transpl."},{"key":"10.1016\/j.antiviral.2013.05.015_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(03)00028-7","article-title":"Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase","volume":"58","author":"De Francesco","year":"2003","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.antiviral.2013.05.015_b0025","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.gastro.2004.09.013","article-title":"Hepatocellular carcinoma: recent trends in the United States","volume":"127","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.antiviral.2013.05.015_b0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/13543784.14.9.1129","article-title":"The therapeutic potential of NS3 protease inhibitors in HCV infection","volume":"14","author":"Goudreau","year":"2005","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2013.05.015_b0035","unstructured":"Lawitz, E., Rodriguez-Torres, M., Stoehr, A., Gane, E.J., Serfaty, L., Bhanja, S., Barnard, R.J., An, D., Gress, J., Hwang, P., Mobashery, N., 2011. A phase 2b study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. In: 62th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA (Abstract LB-13)."},{"issue":"1","key":"10.1016\/j.antiviral.2013.05.015_b0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK-7009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","author":"Liverton","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2013.05.015_b0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jviromet.2008.05.014","article-title":"A transient cell-based phenotype assay for hepatitis C NS3\/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV","volume":"151","author":"Ludmerer","year":"2008","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2013.05.015_b0050","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na\u00efve patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2013.05.015_b0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alf-2b or alf-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2013.05.015_b0060","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.00990-10","article-title":"Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents","volume":"55","author":"Olsen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.05.015_b0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ab.2004.04.027","article-title":"Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells","volume":"331","author":"Pacini","year":"2004","journal-title":"Anal. Biochem."},{"issue":"13","key":"10.1016\/j.antiviral.2013.05.015_b0070","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.05.015_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","article-title":"Global surveillance and control of hepatitis C","volume":"6","author":"Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board","year":"1999","journal-title":"J. Viral Hepat."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T12:27:56Z","timestamp":1539606476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0166354213001551"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.05.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}